Research
Neural
Patients prescribed semaglutide or tirzepatide had an increased risk of other optic nerve disorders with a hazard ratio of 1.65.
Clinicians should be aware of the risk of other optic nerve disorders in patients on semaglutide or tirzepatide.
StrongSupportsmedium confidence
There were 93 patients (0.12%) with other optic nerve disorders in the semaglutide or tirzepatide group and 54 patients (0.07%) with other optic nerve disorders in the matched comparison group (hazard ratio, 1.65 [95% CI, 1.18-2.31]).
Why this rating
Based on a large cohort study design.
Source
Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes
Lindsey Wang et al. · JAMA Network Open · 2025
cohort · n=159398Cited 25×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →